touchONCOLOGY touchONCOLOGY

Press Releases

LONDON, May 22, 2018 /PRNewswire/ — Soumitra Tole, Laura Wheaton, Sarah Alexander, Oncology & Hematology Review. 2018;14(1):21-27 DOI: https://doi.org/10.17925/OHR.2018.14.1.21 Published recently in Oncology & Hematology Review, the peer-reviewed journal from touchONCOLOGY, Tole et al review the pathology, clinical presentation, and prognostic factors for pediatric ALCL, and discuss the therapeutic strategies for the disease. Anaplastic large […]

LONDON, August 15, 2017 /PRNewswire/ — Touch Medical Media today announced the appointment of Dr Brian W Tempest CSci, CChem, FRSC, BSc, PhD, DSc (Hon) to its Board of Directors as Non-Executive Chairman. Brian has worked in the pharmaceutical industry for the last 46 years in both the discovery and generic pharmaceutical industries. This has […]

LONDON, May 25, 2017 /PRNewswire/ — Touch Medical Media has named Prof. Axel Merseburger as the new Editor-in-Chief of their journal European Oncology & Haematology, a peer reviewed, open access journal dedicated to the publication of topical articles in the oncology field. Professor Mersburger, who joined the European Oncology & Haematology Editorial Board last year, […]

LONDON, February 7, 2017 /PRNewswire/ — James Gilbart; European Oncology & Haematology, 2016;12(Suppl 1):i-viii; //www.touchoncology.com/articles/advancing-our-clinical-perspectives-haematology-what-your-approach Published recently in European Oncology & Haematology Review, the peer-reviewed journal from touchONCOLOGY, James Gilbart discusses Essential thrombocythaemia (ET) which is a rare and serious blood disorder that is associated with significant morbidity and mortality, but knowledge of the pathophysiology […]

LONDON, January 19, 2017 /PRNewswire/ — James Gilbart, Axel Grothey; European Oncology & Haematology, 2016;12(Suppl 2):3-8; //www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and Published recently in a supplement to European Oncology & Haematology Review, the peer-reviewed journal from touchONCOLOGY, an article by James Gilbart and Axel Grothey emphasises that both metastatic colorectal cancer (mCRC) and hepatocellular cancer (HCC) are complex diseases. […]

LONDON, December 15, 2016 /PRNewswire/ — Shilpa Gupta, Neeraj Agarwal, Oncology & Hematology Review, 2016;12(2):82-8, https://doi.org/10.17925/OHR.2016.12.02.82 Published recently in Oncology & Hematology Review, the peer-reviewed journal from touchONCOLOGY, Shilpa Gupta discusses high-dose interleukin-2 (HD IL-2), which has been in clinical use in the treatment of metastatic renal cell carcinoma (mRCC) and metastatic melanoma (mM) for over […]

LONDON, December 15, 2016 /PRNewswire/ — Patrick Wuchter, Kai Hübel, European Oncology & Haematology, 2016;12(2):87-92, https://doi.org/10.17925/EOH.2016.12.02.87     Published recently in European Oncology & Haematology Review, the peer-reviewed journal from touchONCOLOGY, Patrick Wuchter and Kai Hubel discuss mobilisation strategies for haematopietic stem cells. Autologous haematopoietic stem-cell transplantation (HSCT) is the standard treatment for a number of haematological […]

LONDON, December 15, 2016 /PRNewswire/ — Jean-Jacques Kiladjian, Yvonne Francis, Juliette Soret, European Oncology & Haematology, 2016;12(2):81-6 DOI: https://doi.org/10.17925/EOH.2016.12.02.81 Published recently in European Oncology & Haematology Review, the peer-reviewed journal from touchONCOLOGY, Jean-Jacques Kiladjian et al, present a review of polycythaemia vera (PV), an uncommon chronic myeloproliferative neoplasm characterised by increased red-cell mass. The condition […]

LONDON, December 15, 2016 /PRNewswire/ — Howard L Kaufman, Oncology & Hematology Review, 2016;12(2):77-9 DOI: https://doi.org/10.17925/OHR.2016.12.02.77    Published recently in Oncology & Hematology Review, the peer-reviewed journal from touchONCOLOGY, Howard L Kaufman discusses the continuing role of high dose interleukin (HD IL-2), an approved therapy for the treatment of metastatic renal cell carcinoma (mRCC) and […]

LONDON, December 15, 2016 /PRNewswire/ — Nicolaus Kröger; European Oncology & Haematology, 2016;12(2):93-5 DOI: https://doi.org/10.17925/EOH.2016.12.02.93    Published recently in European Oncology & Haematology Review, the peer-reviewed journal from touchONCOLOGY, Nicolaus Kröger discusses chronic graft-versus-host disease (GVHD), which is a major cause of late morbidity and mortality post-allogeneic haematopoietic stem cell transplantation. Compared with acute GVHD, […]

LONDON, December 15, 2016 /PRNewswire/ — Karen A Gelmon, European Oncology & Haematology, 2016;12(2):79-80 DOI: https://doi.org/10.17925/EOH.2016.12.02.79 Published recently in European Oncology & Haematology Review, the peer-reviewed journal from touchONCOLOGY, Karen A Gelmon draws attention to the urgent need for new treatments for advanced cancer of the breast, of which the most common subtype is hormone […]

LONDON, December 15, 2016 /PRNewswire/ — Andrew Spencer, Sridurga Mithraprabhu, European Oncology & Haematology, 2016;12(2):96-102 DOI: https://doi.org/10.17925/EOH.2016.12.02.96 Published recently in European Oncology & Haematology Review, the peer-reviewed journal from touchONCOLOGY, Andrew Spencer et al, highlights the critical need for more effective therapies in multiple myeloma (MM) since all patients eventually relapse following front-line treatment. A […]

LONDON, December 22, 2015 /PRNewswire/ — Oncology & Hematology Review, the peer-reviewed journal, has published a review highlighting recent data around rociletinib, an investigational therapy in patients with previously treated EGFR mutant-positive non-small cell lung cancer.

LONDON, November 10, 2015 (PRNewswire) European Oncology & Haematology Review, a peer-reviewed journal, has published a review highlighting the benefits of the Prosigna® (PAM50) Gene Signature Assay, a new-generation genomic test for treatment decision-making in early breast cancer

LONDON, October 15, 2015 /PRNewswire/ – European Oncology & Haematology Review, the peer-reviewed journal, has published a review highlighting the Adverse Event Management in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

(PRWEB UK) 2 June 2015 — European Oncology & Haematology, a peer-reviewed, open access, bi-annual oncology journal published a cutting-edge article by Maria-Domenica Cappellini.

Touch Medical Media, the Provider of Peer-reviewed, Open Access and Multimedia Content, Launch Mobile Optimised Websites Across Their Online Physician Communities.

June 03, 2014 — Oncology & Hematology Review, the peer-reviewed journal, publishes cutting-edge article on Immunologic Therapy of Renal Cell Carcinoma.

London (PRWEB UK) 24 October 2013 – touchONCOLOGY were circulating copies of their latest edition of European Oncology & Haematology Review Volume 9 Issue 1, a free-to-access, peer-reviewed journal aimed at the European market, made up of cutting-edge review articles written by some of the most respected physicians in the world.

London, UK (PRWEB UK) 6 August 2013 — At the same time, Touch Medical Media has signed an updated licensing agreement with Doctors.net.uk, the UK’s largest and most active network of medical professionals, which will see the latter’s 198,000 members gain access to scientific peer-reviewed content across Touch Oncology and Touch Endocrinology globally

touchONCOLOGY, the provider of peer-reviewed, multimedia content from world renowned physicians, profile their re-launched website and latest journal at ASCO 2013

Touch Medical Media splits from Touch Briefings, launches a series of cutting edge, free to access, educational resources and signs an updated media partnership with ECCO, The European CanCer Organisation, a pan-European federation representing 60,000 oncology professionals.

  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72